牛牛AI助理已提取核心訊息
On February 29, 2024, Clene Inc. announced the presentation of positive clinical results from the VISIONARY-MS trial long-term extension (LTE) for its CNM-Au8 30mg treatment in patients with multiple sclerosis (MS). The results were presented at the annual Americas Committee for Treatment and Research in MS (ACTRIMS) Forum 2024. The study showed significant and clinically meaningful improvements in vision and cognition in MS patients over a period of 35 months. The treatment was well-tolerated with high compliance and no serious adverse events attributed to CNM-Au8. Clene Inc., a clinical-stage biopharmaceutical company, focuses on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases. The company's investigational therapy, CNM-Au8, targets mitochondrial function and the NAD pathway while reducing oxidative stress. The VISIONARY-MS trial was a Phase 2 multi-center, randomized, double-blind, placebo-controlled trial that evaluated the efficacy and safety of CNM-Au8 in stable relapsing MS patients with chronic optic neuropathy.
On February 29, 2024, Clene Inc. announced the presentation of positive clinical results from the VISIONARY-MS trial long-term extension (LTE) for its CNM-Au8 30mg treatment in patients with multiple sclerosis (MS). The results were presented at the annual Americas Committee for Treatment and Research in MS (ACTRIMS) Forum 2024. The study showed significant and clinically meaningful improvements in vision and cognition in MS patients over a period of 35 months. The treatment was well-tolerated with high compliance and no serious adverse events attributed to CNM-Au8. Clene Inc., a clinical-stage biopharmaceutical company, focuses on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases. The company's investigational therapy, CNM-Au8, targets mitochondrial function and the NAD pathway while reducing oxidative stress. The VISIONARY-MS trial was a Phase 2 multi-center, randomized, double-blind, placebo-controlled trial that evaluated the efficacy and safety of CNM-Au8 in stable relapsing MS patients with chronic optic neuropathy.
2024年2月29日，Clene Inc.宣佈公佈了其針對多發性硬化症（MS）患者的CNM-Au8 30mg治療的VISIONARY-MS長期延期試驗（LTE）的積極臨床結果。研究結果已在2024年美洲多發性硬化症治療與研究委員會（ACTRIMS）年度論壇上公佈。該研究表明，在35個月的時間裏，多發性硬化症患者的視力和認知能力得到了顯著且具有臨床意義的改善。該治療耐受性良好，依從性高，沒有由於 CNM-Au8 引起的嚴重不良事件。Clene Inc. 是一家處於臨床階段的生物製藥公司，專注於改善線粒體健康和保護神經元功能，以治療神經退行性疾病。該公司的研究性療法CNM-au8靶向線粒體功能和NAD途徑，同時減少氧化應激。VISIONARY-MS試驗是一項2期多中心、隨機、雙盲、安慰劑對照的試驗，旨在評估CNM-Au8對穩定復發的慢性視神經病變多發性硬化症患者的療效和安全性。
2024年2月29日，Clene Inc.宣佈公佈了其針對多發性硬化症（MS）患者的CNM-Au8 30mg治療的VISIONARY-MS長期延期試驗（LTE）的積極臨床結果。研究結果已在2024年美洲多發性硬化症治療與研究委員會（ACTRIMS）年度論壇上公佈。該研究表明，在35個月的時間裏，多發性硬化症患者的視力和認知能力得到了顯著且具有臨床意義的改善。該治療耐受性良好，依從性高，沒有由於 CNM-Au8 引起的嚴重不良事件。Clene Inc. 是一家處於臨床階段的生物製藥公司，專注於改善線粒體健康和保護神經元功能，以治療神經退行性疾病。該公司的研究性療法CNM-au8靶向線粒體功能和NAD途徑，同時減少氧化應激。VISIONARY-MS試驗是一項2期多中心、隨機、雙盲、安慰劑對照的試驗，旨在評估CNM-Au8對穩定復發的慢性視神經病變多發性硬化症患者的療效和安全性。
有用
沒用
